Trial
NCT03866239
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Colorectal Cancer
Intervention
Obinutuzumab
Why stopped
The Sponsor terminated the study because development of cibisatamab has been discontinued.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-09